Recent updates on GLP-1 agonists: current advancements& challenges
Experience physician-prescribed advanced longevity peptide therapy near you across Texas today
The dataset is observational, the comparator is not semaglutide, and the usual real-world-data cautions apply, confounding by indication, residual selection bias, the unmeasured-variable problem that haunts any non-randomized comparison
While Semaglutide focuses solely on GLP-1 receptors, Tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors
Beyond glucose regulation, tirzepatide significantly affects appetite and satiety through central nervous system pathways
Cagrilintide + rztd Combines amylin signaling with GIP/GLP-1 co-agonism for broader metabolic and satiety effects